Successful use of rituximab in fibrillary glomerulopathy.
Fibrillary glomerulopathy (FG) can occur either alone or co-existing with other proteinuric glomerular disorders. FG has been associated with poor renal outcomes leading to End Stage Renal Disease (ESRD). Since FG is a relatively rare disorder, limited information is available concerning treatment protocols. We present two patients with FG who were treated with rituximab after they had already progressed to stage 3 chronic kidney disease (CKD) with worsening proteinuria. Rituximab therapy resulted in long-term stabilization of renal function.
Department of Nephrology, University of Tennessee Health Science Center , Memphis, TN , USA .
Asad
A
Chaudhary
Geeta
G
Gyamlani
Nich L
NL
Cossey
Patrick D
PD
Walker
Barry M
BM
Wall
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab
Chronic kidney disease; fibrillary; glomerulonephritis; rituximab; treatment